Your browser doesn't support javascript.
Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.
Sharma, Rohit; Kumar, Praveen; Rauf, Abdur; Chaudhary, Ashun; Prajapati, Pradeep Kumar; Emran, Talha Bin; Gonçalves Lima, Clara Mariana; Conte-Junior, Carlos Adam.
  • Sharma R; Department of Rasa shastra and Bhaishajya Kalpana, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.
  • Kumar P; Department of Medicinal Chemistry, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.
  • Rauf A; Department of Chemistry, University of Swabi, Swabi, Pakistan.
  • Chaudhary A; Department of Plant Science (Botany), Central University of Himachal Pradesh, Dharamshala, India.
  • Prajapati PK; Department of Rasashastra and Bhaishajya Kalpana, All India Institute of Ayurveda, New Delhi, India.
  • Emran TB; Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, Bangladesh.
  • Gonçalves Lima CM; Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh.
  • Conte-Junior CA; Department of Food Science, Federal University of Lavras, Lavras, MG, Brazil.
Front Cell Infect Microbiol ; 12: 937481, 2022.
Article in English | MEDLINE | ID: covidwho-2039658
ABSTRACT
The second wave of coronavirus disease 2019 (COVID-19) caused severe infections with high mortality. An increase in the cases of COVID-19-associated mucormycosis (CAM) was reported predominantly in India. Commonly present in immunocompromised individuals, mucormycosis is often a life-threatening condition. Confounding factors and molecular mechanisms associated with CAM are still not well understood, and there is a need for careful research in this direction. In this review, a brief account of the diagnosis, management, and advancement in drug discovery for mucormycosis has been provided. Here, we summarize major factors that dictate the occurrence of mucormycosis in COVID-19 patients through the analysis of published literature and case reports. Major predisposing factors to mucormycosis appear to be uncontrolled diabetes, steroid therapy, and certain cancers. At the molecular level, increased levels of iron in COVID-19 might contribute to mucormycosis. We have also discussed the potential role and regulation of iron metabolism in COVID-19 patients in establishing fungal growth. Other factors including diabetes prevalence and fungal spore burden in India as contributing factors have also been discussed.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus / COVID-19 / Mucormycosis Type of study: Diagnostic study / Etiology study / Observational study Topics: Long Covid Limits: Humans Country/Region as subject: Asia Language: English Journal: Front Cell Infect Microbiol Year: 2022 Document Type: Article Affiliation country: Fcimb.2022.937481

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus / COVID-19 / Mucormycosis Type of study: Diagnostic study / Etiology study / Observational study Topics: Long Covid Limits: Humans Country/Region as subject: Asia Language: English Journal: Front Cell Infect Microbiol Year: 2022 Document Type: Article Affiliation country: Fcimb.2022.937481